Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Page 5 of 7
Apr 5, 2026Industry experts suggest that the future leaders in healthcare AI will be distinguished by their ability to embed their technology within existing medical environments, leverage unique data assets, and effectively navigate commercialization challenges. This analysis delves into the key factors that could determine winners and losers in the evolving healthcare AI landscape.
Apr 1, 2026The infusion of $17 million from investors including M13 and Town Hall Ventures will enable Jimini Health to scale its AI platform Sage, which integrates clinician supervision to provide complex mental health care. This development marks a significant step in AI-driven behavioral health solutions.
Mar 31, 2026Mass General Brigham has established a rigorous process for deciding which artificial intelligence tools are worth deploying across their health system. This careful evaluation aims to balance innovation with patient safety and operational effectiveness.
Mar 29, 2026The recent commercialization agreement between Lilly and AI drug developer Insilico Medicine represents the growing impact of AI technologies in pharmaceutical research and development. With $115 million upfront and potential biobucks totaling approximately $2.75 billion, this partnership underscores the transformative role AI now plays in drug discovery and commercialization processes.
Mar 29, 2026Health systems are increasingly leveraging AI technologies that predict risks with growing accuracy. However, meaningful improvements in preventive care delivery require combining these insights with deliberate human outreach and healthcare planning. This synergy is central to harnessing AI’s full potential to expand access.
Mar 28, 2026UnitedHealthcare’s introduction of Avery marks a step forward in integrating artificial intelligence to enhance patient experience. Avery combines advanced AI capabilities with live support to streamline healthcare management for users.
Mar 25, 2026The application of artificial intelligence in rural healthcare settings is helping bridge gaps in specialist availability. By integrating Eko Health’s AI-enabled digital stethoscope, Wayne General Hospital exemplifies how technology can improve early detection of heart disease in underserved areas.
Mar 23, 2026Earendil Labs has rapidly emerged as a frontrunner in AI-driven drug discovery platforms, having generated over 40 development programs. This latest investment, backed by industry leaders Sanofi and Pfizer, signifies strong confidence in AI’s transformative role in biopharmaceutical innovation.
Mar 22, 2026Utah’s innovative pilot program using an AI-powered system by Doctronic aims to streamline routine prescription refills to reduce delays and improve medication adherence. However, recent reports indicating vulnerabilities in the AI chatbot used reveal the broader complexities and risks that come with deploying AI systems in healthcare environments. This case study exemplifies the delicate balance between technological advancement and ensuring patient safety.
Mar 21, 2026Investing in healthcare AI requires a nuanced approach that addresses the complex dynamics of the industry. This article explores how venture capitalists make investment decisions with a focus on discerning the most promising healthcare AI companies.
Mar 13, 2026Waiv, which originated as the diagnostics division of AI-driven biotech company Owkin, has spun out as an independent entity with substantial new capital to propel its AI-based cancer diagnostic tools. This spinout will enable the company to focus more sharply on advancing precision medicine and clinical applications in oncology.
Mar 13, 2026Amid a wave of technological advances, Microsoft has entered the healthcare AI chatbot space with Copilot Health. By aggregating diverse health data sources, the platform is positioned to support users with personalized medical insights, reflecting the expanding role of artificial intelligence in healthcare delivery.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.